Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012
about
The positive clinical therapeutically effects of Escin on advanced thyroid cancer.Timing of multikinase inhibitor initiation in differentiated thyroid cancer.Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.Update on the treatment of hypothyroidismRadioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer.Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer.Dual control of pituitary thyroid stimulating hormone secretion by thyroxine and triiodothyronine in athyreotic patients.Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.Higher expression level of tyrosine kinase-like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis.Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated ThyroglobuliFollicular cell-derived thyroid cancer.BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).Secondary Salivary Gland Malignancy in Thyroid Cancer: A United States Population Based Study.BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI)
P2860
Q33679565-04D41B7D-1DEF-4F74-AFE8-287CAECEC673Q33733408-BF46054B-E227-4199-A887-D4FD45C2E652Q36108073-FFC647B2-F686-4F16-82B8-CE129941371BQ36425038-4755AD12-DB23-4B8A-B24D-DA1B7B4C8EA4Q37404779-A2855B0B-10C0-4F2C-9DB6-26BE1FB0376FQ38716870-98160FA4-502D-428E-93F0-604AABB042BFQ38743211-8EEF736C-8085-42D9-A1F2-3D464490FD84Q41105417-2D458421-8486-44E8-A909-FA5CE4192863Q47096509-B3B3784A-0CB8-4E0A-A867-6B2382006E71Q47162063-45872B80-A727-45EE-B035-FB4F196C193CQ48096442-3A476D47-6C90-4751-B141-9128BCACB46CQ48651339-8F119496-B636-4915-B916-9B54E0345ED5Q49808093-63B8B057-2C85-4AEA-995C-51BAD139AEE0Q50067340-5B31E927-1C1E-4A9E-9F91-C19BF513BD43Q55470775-7271C1B9-E3EE-497F-8D29-E4729658C587Q58776034-2D4E46BE-CC1E-4364-90FB-67002A81C618
P2860
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@ast
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@en
Long-Term Outcomes Following T ...... S Registry Analysis 1987-2012.
@nl
type
label
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@ast
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@en
Long-Term Outcomes Following T ...... S Registry Analysis 1987-2012.
@nl
prefLabel
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@ast
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@en
Long-Term Outcomes Following T ...... S Registry Analysis 1987-2012.
@nl
P2093
P2860
P356
P1476
Long-Term Outcomes Following T ...... CS Registry Analysis 1987-2012
@en
P2093
Aubrey A Carhill
Bryan R Haugen
Danielle R Litofsky
David L Steward
David S Cooper
Douglas S Ross
Harry R Maxon
Henry G Fein
James D Brierley
James Magner
P2860
P304
P356
10.1210/JC.2015-1346
P407
P577
2015-07-14T00:00:00Z